AI English summary of an SEC filing — figures as filed
Charles River Laboratories CRLThe company said revenue for the 3 months ended September 28, 2024 decreased $1,009.8 million, or 1.6%, to $16.9 million, and operating income was $117.4 million, or 11.6% of revenue, lower than $151.5 million, or 14.8%, in the same period of 2023.
Key points
AI summaryThe company said revenue for the 3 months ended September 28, 2024 decreased $1,009.8 million, or 1.6%, to $16.9 million, and operating income was $117.4 million, or 11.6% of revenue, lower than $151.5 million, or 14.8%, in the same period of 2023.
Charles River Laboratories said DSA revenue fell $49.0 million over the 3 months, while RMS revenue was $11.0 million and Manufacturing revenue rose $21.1 million. The company cited lower volume in Safety Assessment and lower demand in Discovery Services as the reasons for the DSA decline.
The company said it is cooperating with the DOJ and USFWS investigation into Cambodia-sourced non-human primate shipments and with SEC requests for information, and that the carrying value of inventory related to Cambodia-sourced shipments was approximately $27 million as of September 28, 2024.
The company said operating cash flow for the 9 months was $575.2 million ($463.0 million in the same period last year). It also said it repurchased 0.5 million shares for $100.7 million under the $1 billion share repurchase program approved on August 2, 2024, leaving $899.3 million remaining.
Key figures
Quarter ended September 28, 2024
- Revenue
- $1.0B
- Operating income
- $117M
- Net income
- $70M
- EPS
- $1.33
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
3-Month Revenue and Operating Income
The company said revenue for the 3 months ended September 28, 2024 decreased $1,009.8 million, or 1.6%, to $16.9 million, and operating income was $117.4 million, or 11.6% of revenue, lower than $151.5 million, or 14.8%, in the same period of 2023.
Source · Based on the MD&A text of the filing
Segment Revenue Changes for the 3 Months
Charles River Laboratories said DSA revenue fell $49.0 million over the 3 months, while RMS revenue was $11.0 million and Manufacturing revenue rose $21.1 million. The company cited lower volume in Safety Assessment and lower demand in Discovery Services as the reasons for the DSA decline.
Source · Based on the MD&A text of the filing
U.S. Government Investigations into Non-Human Primate Supply Chain
The company said it is cooperating with the DOJ and USFWS investigation into Cambodia-sourced non-human primate shipments and with SEC requests for information, and that the carrying value of inventory related to Cambodia-sourced shipments was approximately $27 million as of September 28, 2024.
Source · Based on the MD&A text of the filing
Operating Cash Flow and Share Repurchases for 9 Months
The company said operating cash flow for the 9 months was $575.2 million ($463.0 million in the same period last year). It also said it repurchased 0.5 million shares for $100.7 million under the $1 billion share repurchase program approved on August 2, 2024, leaving $899.3 million remaining.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…